{"podcast":{"title":"Charged Alpha Stock Encyclopedia","slug":"charged-alpha-stock-encyclopedia-7819792","podcast_index_feed_id":7819792,"rss_url":"https://feed.podbean.com/chargedalpha/feed.xml","website_url":"https://chargedalpha.podbean.com","image_url":"https://pbcdn1.podbean.com/imglogo/image-logo/22241603/charged_alpha_logo_2048.png","author":"Colton Thomas","episode_count":1630,"summary":"Charged Alpha reviews earnings for each stock in the Russel 1000 every quarter. Each podcast gives thorough analysis, along with an in-depth profile in the beginning of the episode of the company, what they do, how they earn money and what to look for.","last_synced_at":"2026-09-04T06:17:14.359815+00:00","page_url":"https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792"},"episode":{"title":"Grifols (GRFS): Profit Jumped 29% — Until You Find the €109M Accounting Gain","slug":"grifols-grfs-profit-jumped-29-until-you-find-the-109m-accounting-gain","published_at":"2026-07-29T16:33:29+00:00","page_url":"https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792/grifols-grfs-profit-jumped-29-until-you-find-the-109m-accounting-gain","show_page_url":"https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792","url":"https://chargedalpha.podbean.com/e/grifols-grfs-profit-jumped-29-%e2%80%94-until-you-find-the-e109m-accounting-gain/","audio_url":"https://mcdn.podbean.com/mf/web/s0uh207d3ui12dx5/audio_d.mp3","summary":"Grifols, S.A. (GRFS) H1 2026 — Grifols, S.A. (NASDAQ: GRFS), the Barcelona-based plasma fractionator and one of only a handful of companies worldwide that can turn donated blood plasma into immunoglobulins, albumin and alpha-1 at scale, reported Half-Year 2026 results after the European close on July 28: revenue of €3,574M, +2.6% at constant currency but -2.8% as reported (a ~€197M FX translation drag), adjusted EBITDA of €854M at a 23.9% margin (+2.4% cc), and group profit of €227M, +28.7% YoY. Q2 standalone adjusted EBITDA of €472M at a 25.2% margin edged past ~€467M consensus. Free cash flow before M&A turned positive at +€91M versus -€12M a year earlier. But the headline profit jump is largely an accounting artifact: the April refinancing was treated under IFRS 9 as a debt modification rather than an extinguishment, producing a €109M NON-CASH gain in the finance result — more than the entire €50M increase in group profit. Strip it and H1 profit is nearer €145M, down ~18%. Net leverage was 4.2x on the credit-agreement basis — exactly where it stood a year ago — and 5.4x on full balance-sheet debt of €8,843M including leases. Adjusting for the €72M of LTM EBITDA consolidated from Haema and BPC Plasma (entities Grifols controls but whose equity its shareholders do not own) puts look-through leverage nearer 4.5x. Immunoglobulin grew +12.8% cc (subcutaneous/Xembify +17.7% H1, +33.9% in Q2), but albumin fell -14.2% cc (-20.8% in Q2) on a China price concession — and albumin is a joint product of the same litre of plasma. FY26 guidance was reaffirmed (adj. EBITDA margin ≥25%, +5-9% cc growth, FCF €500-575M), but H1 delivered 23.9% and +2.4%, so the second half must carry €409-484M of FCF, roughly 5x the H1 run rate. Critically, one GRFS ADR = one Class B NON-VOTING pr…","meta_description":"Grifols, S.A. (GRFS) H1 2026 — Grifols, S.A. (NASDAQ: GRFS), the Barcelona-based plasma fractionator and one of only a handful of companies worldwide that…","key_points":[],"chapters":[],"topics":[],"duration_seconds":938,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/charged-alpha-stock-encyclopedia-7819792/episodes/grifols-grfs-profit-jumped-29-until-you-find-the-109m-accounting-gain/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792/grifols-grfs-profit-jumped-29-until-you-find-the-109m-accounting-gain.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}